Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02899052
Recruitment Status : Recruiting
First Posted : September 14, 2016
Last Update Posted : October 31, 2018
Genentech, Inc.
Onyx Therapeutics, Inc.
Information provided by (Responsible Party):

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : March 27, 2020
  Estimated Study Completion Date : October 16, 2022